Dexcom CEO Jacob Leach Sells 1,451 Shares for Tax Withholding

What Happened

• Jacob Steven Leach, President, CEO and a director of DexCom, disposed of 1,451 shares on Aug 22, 2026 at an effective price of $92.34 per share, for a reported value of $133,985. The transaction is reported as tax withholding related to the net settlement of restricted stock units (RSUs), not an open-market sale by the reporting person.

Key Details

• Transaction date and price: Aug 22, 2026; 1,451 shares at $92.34 each (total $133,985).
• Transaction code: F — tax withholding to satisfy tax withholding/remittance on RSU settlement.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Filing date: Form 4 filed Aug 25, 2026. The filing does not indicate a late filing flag.
• Relevant footnotes:
  • F1: Withheld shares were used to cover tax obligations on net-settled RSUs and "does not represent a sale by the Reporting Person."
  • F2: The reporting person has 142,836 unvested RSUs (breakdown: 104,516 granted Mar 8, 2026 vesting through Mar 8, 2029; 23,937 granted Mar 8, 2025 vesting through Mar 8, 2028; 5,699 granted Mar 8, 2025 vesting through Mar 8, 2027; 8,684 granted Mar 8, 2024 vesting through Mar 8, 2027).
  • F3: Certain shares are held by the Gregg Family Grandchildren's Trust (spouse is a trustee).

Context

• This was a routine withholding of shares to cover tax on vested RSUs (a common “net settlement” process), not an open‑market sale indicating a change in investment view. For retail investors, tax-withholding dispositions typically reflect vesting mechanics rather than trading decisions by the insider.